Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

Phase 2 Not yet recruiting 90 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.

Timeline

Start: 2025-07
Primary completion: 2026-04
Completion: 2026-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SSS17	Small molecule	—	Oral

Indications

No indication recorded.